US20230137870A1 - Use of mitochondrial extract to treat and/or prevent kidney injury-related disease - Google Patents
Use of mitochondrial extract to treat and/or prevent kidney injury-related disease Download PDFInfo
- Publication number
- US20230137870A1 US20230137870A1 US17/912,394 US202117912394A US2023137870A1 US 20230137870 A1 US20230137870 A1 US 20230137870A1 US 202117912394 A US202117912394 A US 202117912394A US 2023137870 A1 US2023137870 A1 US 2023137870A1
- Authority
- US
- United States
- Prior art keywords
- kidney
- injury
- cells
- mitochondrial
- renal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002438 mitochondrial effect Effects 0.000 title claims abstract description 43
- 206010061481 Renal injury Diseases 0.000 title claims abstract description 33
- 208000037806 kidney injury Diseases 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 26
- 239000000284 extract Substances 0.000 title abstract description 20
- 210000003470 mitochondria Anatomy 0.000 claims description 36
- 208000027418 Wounds and injury Diseases 0.000 claims description 21
- 230000006378 damage Effects 0.000 claims description 21
- 208000014674 injury Diseases 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 14
- 208000037978 tubular injury Diseases 0.000 claims description 10
- 230000010024 tubular injury Effects 0.000 claims description 10
- 208000020832 chronic kidney disease Diseases 0.000 claims description 9
- 206010023421 Kidney fibrosis Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000006866 deterioration Effects 0.000 abstract description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 52
- 210000002919 epithelial cell Anatomy 0.000 description 50
- 238000012258 culturing Methods 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 238000011282 treatment Methods 0.000 description 21
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 16
- 239000007788 liquid Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 239000012894 fetal calf serum Substances 0.000 description 13
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000008055 phosphate buffer solution Substances 0.000 description 11
- 210000000130 stem cell Anatomy 0.000 description 11
- 229940109239 creatinine Drugs 0.000 description 9
- 210000003292 kidney cell Anatomy 0.000 description 9
- 208000017169 kidney disease Diseases 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 206010016654 Fibrosis Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000004761 fibrosis Effects 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 201000002793 renal fibrosis Diseases 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 208000037157 Azotemia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000009852 uremia Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- VVBXXVAFSPEIJQ-CVIPOMFBSA-N [(2r)-3-[[(2r)-1-[[(2s,5r,8r,11r,12s,15s,18s,21s)-15-[3-(diaminomethylideneamino)propyl]-21-hydroxy-5-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,6,9,13,16,22-hexaoxo-8-propan-2-yl-10-oxa-1,4,7,14,17-pentazabicyclo[16.3.1]docosan-12-yl]am Chemical compound C([C@@H]1C(=O)N[C@@H](C(=O)O[C@H](C)[C@@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H]2CC[C@H](O)N(C2=O)[C@@H](CC(C)C)C(=O)N1C)=O)NC(=O)[C@H](NC(=O)[C@H](O)COS(O)(=O)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 VVBXXVAFSPEIJQ-CVIPOMFBSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 210000003663 amniotic stem cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004991 placental stem cell Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
Definitions
- the present invention relates to a second use of a mitochondrial extract, and in particular to a use of a mitochondrial extract to treat and/or prevent a kidney injury-related disease.
- the mitochondrion is an organelle in human cells that provides the ATP required for the normal operation of cells.
- an increase in the number and the activation of the mitochondria in cells can provide energy required for differentiation of stem cells and help the stem cells successfully differentiate.
- the mitochondria feature prominently in human energy metabolism.
- defects in the mitochondria are likely to cause degenerative or aging-related diseases, such as brain degeneration, muscle weakness, muscle diseases, etc.
- Many current studies point out that if patients with the Parkinson's or Alzheimer's disease caused by oxidative damage can maintain normal functions of the mitochondria or enhance an antioxidant capacity in the body, neurodegenerative diseases can be stopped from getting worse.
- kidney tissue When the kidney tissue is injured for more than 3 months so that the structure or function of the kidney cannot be restored to the original status, it is called a chronic kidney disease.
- most clinical treatments are based on drug therapy, supplemented by diet and lifestyle control.
- the chronic kidney disease gradually worsens with the course of the disease, the patients are faced with kidney fibrosis and gradually lose the kidney functions.
- the patients need hemodialysis is or kidney transplantation to sustain life, which is not only a very uncomfortable process for the patients, but also a high burden on national medical cost.
- the pathogenesis and the treatment of the chronic kidney disease neither have been confirmed, there is no effective clinical treatment for the chronic kidney disease. Therefore, in clinical medicine, it is in urgent need to provide a composition or method for effectively treating the chronic kidney disease and renal fibrosis.
- the main objective of the present invention is to provide a second use of a mitochondrial extract, which can effectively alleviate or prevent a kidney injury-related disease, thus achieving the effect of treating the kidney disease or slowing down the progression of the kidney disease.
- the present invention discloses a use of mitochondria to prepare a composition for preventing and/or treating a kidney injury-related disease. Specifically, by administering a certain amount of mitochondrial extracts to a patient having a kidney injury-related disease, the injury in the kidney cells can be alleviated, thus treating the kidney injury-related disease or preventing deterioration.
- the kidney injury-related disease is renal fibrosis, renal inflammation, a chronic kidney disease, an acute kidney disease, a renal tubular injury, renal failure, a prerenal injury, a renal induced injury, a postrenal injury, glomerulitis, pyelonephritis, nephrotic syndrome, uremia, or the like.
- the kidney injury-related disease has a mitochondrial injury and at least one of the following symptoms: Proteinuria, edema, oliguria, high urea nitrogen, high creatinine, abnormal uric acid, kidney stone, and an abnormal glomerular filtration rate,
- the mitochondria are separated out from stem cells, such as adipose-derived stem cells, CD34+ hematopoietic stem cells, mesenchymal stem cells, bone stem cells, umbilical stem cells, amniotic stem cells, amniotic fluid stem cells, placental stem cells, iPS, or neural stem cells.
- stem cells such as adipose-derived stem cells, CD34+ hematopoietic stem cells, mesenchymal stem cells, bone stem cells, umbilical stem cells, amniotic stem cells, amniotic fluid stem cells, placental stem cells, iPS, or neural stem cells.
- the dose of the mitochondria in the composition ranges from 5 ⁇ g to 80 ⁇ g, and is preferably 40 ⁇ g or more.
- the mitochondrial damage occurs in kidney cells due to fibrosis, oxidative stress or inflammatory environment
- administration of the mitochondrial extract or the composition containing the mitochondrial extract provided by the present invention can effectively improve the mitochondrial damage of kidney cells, therefore it can improve or treat renal cell damage or related diseases.
- FIG. 1 A shows a statistical analysis result of a survival rate of renal epithelial cells subjected to treatment with different concentrations of hydrogen peroxide for 24 hours;
- FIG. 1 B shows a statistical analysis result of a survival rate of renal epithelial cells subjected to treatment with different concentrations of hydrogen peroxide and then administered with different doses of mitochondrial precipitates;
- FIG. 2 A shows a detection and analysis result of a collagen secretion amount from the renal epithelial cells after the cells are subjected to treatment with different concentrations of Advanced glycation end-products (AGEs-B SA) for different lengths of time;
- AGEs-B SA Advanced glycation end-products
- FIG. 2 B shows a detection and analysis result of a collagen secretion amount from the renal epithelial cells after the cells are subjected to treatment with different concentrations of AGES-BSA and then administered with different doses of mitochondrial precipitates;
- FIG. 2 C shows a detection and analysis result of a collagen secretion amount from the renal epithelial cells after the cells are subjected to treatment with different concentrations of hydrogen peroxide and then administered with different doses of mitochondrial precipitates;
- FIG. 3 shows a detection and analysis result of a mitochondrial injury in the renal epithelial cells after the cells are subjected to treatment with hydrogen peroxide or AGEs-BSA and then administered with different doses of mitochondrial precipitates.
- the present invention provides a second use of a mitochondrial extract, which can effectively alleviate a kidney injury-related disease and prevent the progression of the disease by administering a certain amount of mitochondrial extracts or a composition containing the mitochondrial extracts to a patient having the kidney injury-related disease.
- the patient administration dose of the mitochondria disclosed in the present invention ranges from 5 ⁇ g to 80 ⁇ g, such as 5 ⁇ g, 10 ⁇ g, 15 ⁇ g, 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 40 ⁇ g, 50 ⁇ g, 60 ⁇ g, 65 ⁇ g, 70 ⁇ g, or 80 ⁇ g, and preferably ranges from 15 ⁇ g to 40 ⁇ g.
- the mitochondria disclosed in the present invention can be mixed with another component to prepare a composition, where the used component is preferably a material having growth factors, such as a blood product containing growth factors, platelet-rich plasma (PRP), plasma, serum, platelet-rich fibrin (PRF), or the like.
- a blood product containing growth factors such as a blood product containing growth factors, platelet-rich plasma (PRP), plasma, serum, platelet-rich fibrin (PRF), or the like.
- PRP platelet-rich plasma
- PRF platelet-rich fibrin
- mitochondria extract refers to mitochondria separated out from cells, and the used separation technique or method should be able to maintain the structural and functional integrity of the mitochondria.
- the separation technique or method may be physical or chemical.
- the “cells” mentioned in the present invention refer to those having mitochondria, such as adipose-derived stem cells, mesenchymal stem cells, skeletal muscle cells, liver cells, kidney cells, fibroblasts, nerve cells, skin cells, blood cells, and the like.
- composition refers to a medical compound, food, functional food, nutritional supplement, etc., and is formed by mixing different components according to different types, to obtain different dosage forms and different administration methods.
- kidney injury-related disease refers to a disease caused by damage to kidney cells and has symptoms of a mitochondrial injury, such as renal fibrosis, renal inflammation, a renal disease, an acute kidney disease, a renal tubular injury, renal failure, a prerenal injury, a renal induced injury, a postrenal injury, glomerulitis, pyelonephritis, nephrotic syndrome, uremia, or the like.
- a mitochondrial injury such as renal fibrosis, renal inflammation, a renal disease, an acute kidney disease, a renal tubular injury, renal failure, a prerenal injury, a renal induced injury, a postrenal injury, glomerulitis, pyelonephritis, nephrotic syndrome, uremia, or the like.
- the mitochondria used in the following examples are taken from human adipose-derived stem cells, but the mitochondria of the present invention are not limited to only coming from the human adipose-derived stem cells. That is, the mitochondria of the present invention can be taken from any human cell.
- the doses of the mitochondria used in the following examples are merely exemplary, where the dose of 15 ⁇ g of the mitochondria is used as a low-dose representative and the dose of 40 ⁇ g is used as a high-dose representative; and the doses are not intended to limit the technical features of the present invention. That is, the doses of 5 ⁇ g to 80 ⁇ g of the mitochondria disclosed in the present invention can all achieve the effects to be achieved by the present invention.
- the culture of renal epithelial cell strains was performed in a cell culture medium that contains MEM- ⁇ Earl's salt and 5% fetal calf serum in a 37° C. environment (containing 5% carbon dioxide).
- the cell culture medium was removed and the phosphate buffer solution was used for rinsing the cells.
- the phosphate buffer solution was removed and 0.25% trypsin or 2.21 mM EDTA was added in to react for 20 min, then MEM- ⁇ containing 5% fetal calf serum was added in to neutralize the trypsin, and cells in suspension were collected and centrifuged. Then, the cells were counted, and diluted by using MEM- ⁇ containing 5% fetal calf serum to a final concentration of 5 ⁇ 10 4 cells per ml, for use in the subsequent subculture or analysis.
- the human adipose-derived stem cells were cultured to obtain 1.5 ⁇ 10 8 cells, and the Duchenne phosphate buffer solution (DPBS) was used to flush the cells and then was removed. Trypsin was added in to react for 3 min, and then a stem cell culture liquid (Keratinocyte SFM (1X) liquid, bovine pituitary extract, or 10 wt % fetal calf serum) was added in to terminate the reaction. Afterwards, the cells were collected and centrifuged (600 g for 10 min), and the supernatant was removed.
- DPBS Duchenne phosphate buffer solution
- the buffer solution is compounded of 225 mM mannitol, 75 mM sucrose, 0.1 mM EDTA, and 30 mM Tris-HCl with pH of 7.4
- 80 ml IBC-1 buffer solution was added to the cells, and centrifugation was conducted after homogenization, to obtain a precipitate which was the mitochondria (referred to as a mitochondrial precipitate in the following description).
- 1.5 ml IBC-1 buffer solution and a proteolytic enzyme inhibitor were added to the mitochondrial precipitate, and then the mitochondrial precipitate was placed aside in a 4° C. environment, for use in the following examples.
- the renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate, where the concentration per well was 5 ⁇ 10 4 cells/200 ⁇ L. After 8-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing. Afterwards, 2004, cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 8 hours, and after culturing, different concentrations of hydrogen peroxide (0.3 mM, 0.5 mM, 1 mM, 3 mM, 5 mM, and 10 mM) were separately added for treatment.
- the survival rate of the renal epithelial cells is 81.4%; after the renal epithelial cells are treated for 24 hours by using hydrogen peroxide with a concentration of 5 mM, the survival rate of the renal epithelial cells is 31.3%; and after the renal epithelial cells are treated for 24 hours by using hydrogen peroxide with a concentration of 10 mM, the survival rate of the renal epithelial cells is 24.2%.
- Example 1 The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate, where the concentration per well was 1 ⁇ 10 4 cells/200 ⁇ L. After 8-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing. Afterwards, 2000 ⁇ L cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 8 hours.
- the survival rate of the renal epithelial cells decreases because the cells are injured after treatment with the hydrogen peroxide.
- the survival rate of the renal epithelial cells can be significantly improved.
- the survival rate of the renal epithelial cells also rises.
- the mitochondrial extract disclosed in the present invention can indeed protect the renal epithelial cells against injuries caused by oxidation or inflammation, and can repair the injured renal epithelial cells, thus efficiently avoiding the renal epithelial cells from death.
- the mitochondrial extract disclosed in the present invention or a composition containing the mitochondrial extract can indeed alleviate and/or prevent a kidney injury or kidney disease due to oxidative stress.
- the renal epithelial cells cultured in Example 1 were cultured in a 6-well plate by using a culture liquid containing 5% fetal calf serum, where the concentration per well was 1 ⁇ 10 5 cells/2 ml. After 24-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing. Afterwards, 1 ml cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 8 hours. Then, different concentrations (100 ⁇ g/ml and 400 ⁇ g/ml) of Advanced Glycation End product-BSA (AGES-BSA) were administered to perform culturing for 4 hours.
- AGES-BSA Advanced Glycation End product-BSA
- the cell culture medium containing AGEs-B SA was removed and the phosphate buffer solution was used for rinsing. Then, 1 ml cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 24 and 48 hours separately, and the supernatant was separately collected after culturing completion.
- a collagen secretion assay was performed by using the SircolTM Soluble Collagen Assay Kit, to obtain a result shown in FIG. 2 A .
- the process of this example was substantially identical with that in Example 5, but had the following differences.
- a cell culture liquid not containing 5% fetal calf serum and different doses (15 ⁇ g and 40 ⁇ g) of mitochondrial precipitates prepared in Example 2 were added to each well for separately culturing for 24 hours. After culturing completion, the supernatant was separately collected and a collagen secretion assay was performed by using the soluble collagen assay kit, to obtain a result shown in FIG. 2 B .
- the administration of the mitochondrial precipitates can reduce the amount of collagen secretion induced by AGEs-BSA in the renal epithelial cells, which indicates that the mitochondria or a composition containing the mitochondria disclosed in the present invention can efficiently alleviate and/or prevent kidney fibrosis or the related kidney diseases.
- the process of this example was substantially identical with that in Example 6, but had the following difference.
- the stimulant that induces fibrosis in the renal epithelial cells was changed from AGEs-BSA to hydrogen peroxide, to obtain a result shown in FIG. 2 C .
- the treatment of the renal epithelial cells with the hydrogen peroxide can induce an increase in the collagen secretion amount, that is, the treatment of the renal epithelial cells with the hydrogen peroxide can indeed construct a pattern of renal cell fibrosis.
- the collagen secretion amount in the renal epithelial cells can be obviously reduced, which indicates that the mitochondria or a composition containing the mitochondria disclosed in the present invention can efficiently alleviate and/or prevent kidney fibrosis or the related kidney diseases.
- the renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate by using a cell culture liquid containing 5% fetal calf serum, where the concentration per well was 5 ⁇ 10 4 cells/200 ⁇ L. After 24-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing; and then 1 ml cell culture liquid not containing 5% fetal calf serum was added to each well to perform culturing for 8 hours.
- the phosphate buffer solution was used for rinsing, and a buffer solution containing 10 ⁇ M JC-1 staining reagent was then added in to react for 10 min at 37° C. After rinsing, fluorescent signal measurement (Excitation/Emission: 488/530 nm) was performed, to obtain a result shown in FIG. 3 .
- I/R kidney injury pattern An ischemia-reperfusion (referred to as an “I/R kidney injury pattern” in the following description) pattern was used as the kidney injury pattern of the mice, and the steps were as follows: First, intraperitoneal injection was conducted and 150 mg/Kg phenobarbital was injected into the abdomen of each mouse. When the mouse was unconscious, surgery was performed on the left kidney of the mouse. The left kidney was moved to the outside from the incision, and then the blood vessel for the renal artery to flow into the kidney was blocked with a vascular clamp. After blocking for 30 min, the vascular clamp was removed to allow the blood flow to pass, thus completing the I/R kidney injury pattern.
- mice subjected to treatment of the UR kidney injury pattern different doses (15 ⁇ g and 40 ⁇ g) of mitochondria were delivered to the kidney by means of injection through the renal artery vessel, to form a high mitochondrial dose group and a low mitochondrial dose group.
- the control group I/R group
- the phosphate buffer solution was injected.
- the kidneys were separately moved back into the bodies and the wounds were sutured; and on the first day (D1) and the second day (D2) after surgery for each group of mice, the blood samples were collected, and the serum creatinine (Cr) and the blood urea nitrogen (BUN) were measured.
- the drawn blood was centrifuged and the serum was collected after separation, to analyze the contents of urea nitrogen and creatinine in the serum, where the detection of serum creatinine was made by using a mouse creatinine analysis kit (Brand: Crystal Chem; Model: 80350) and the detection of urea nitrogen was made by using a urea analysis kit (Brand: abcam; Model: ab83362).
- a mouse creatinine analysis kit (Brand: Crystal Chem; Model: 80350)
- a urea analysis kit Brand: abcam; Model: ab83362
- the degree of kidney injuries was scored as follows by using the Jablonski's semi-quantitative criteria: 0 for normal tissue; 1 for the renal tubular injury area of less than 5%; 2 for the renal tubular injury area of more than 5% to less than 25%; 3 for the renal tubular injury area of greater than 25% to less than 75%; and 4 for the renal tubular injury area of greater than 75%.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
The present invention discloses a use of a mitochondrial extract to treat and/or prevent a kidney injury-related disease. Specifically, by administering the mitochondrial extract disclosed in the present invention to a patient having a kidney injury-related disease, the kidney injury-related disease can be effectively alleviated and prevented from deterioration.
Description
- The present invention relates to a second use of a mitochondrial extract, and in particular to a use of a mitochondrial extract to treat and/or prevent a kidney injury-related disease.
- The mitochondrion is an organelle in human cells that provides the ATP required for the normal operation of cells. Moreover, recent studies point out that an increase in the number and the activation of the mitochondria in cells can provide energy required for differentiation of stem cells and help the stem cells successfully differentiate. In other words, the mitochondria feature prominently in human energy metabolism. For example, defects in the mitochondria are likely to cause degenerative or aging-related diseases, such as brain degeneration, muscle weakness, muscle diseases, etc. Many current studies point out that if patients with the Parkinson's or Alzheimer's disease caused by oxidative damage can maintain normal functions of the mitochondria or enhance an antioxidant capacity in the body, neurodegenerative diseases can be stopped from getting worse.
- When the kidney tissue is injured for more than 3 months so that the structure or function of the kidney cannot be restored to the original status, it is called a chronic kidney disease. Currently, most clinical treatments are based on drug therapy, supplemented by diet and lifestyle control. However, when the chronic kidney disease gradually worsens with the course of the disease, the patients are faced with kidney fibrosis and gradually lose the kidney functions. In this case, the patients need hemodialysis is or kidney transplantation to sustain life, which is not only a very uncomfortable process for the patients, but also a high burden on national medical cost. In other words, because the pathogenesis and the treatment of the chronic kidney disease neither have been confirmed, there is no effective clinical treatment for the chronic kidney disease. Therefore, in clinical medicine, it is in urgent need to provide a composition or method for effectively treating the chronic kidney disease and renal fibrosis.
- The main objective of the present invention is to provide a second use of a mitochondrial extract, which can effectively alleviate or prevent a kidney injury-related disease, thus achieving the effect of treating the kidney disease or slowing down the progression of the kidney disease.
- Therefore, in order to achieve the foregoing objective, the present invention discloses a use of mitochondria to prepare a composition for preventing and/or treating a kidney injury-related disease. Specifically, by administering a certain amount of mitochondrial extracts to a patient having a kidney injury-related disease, the injury in the kidney cells can be alleviated, thus treating the kidney injury-related disease or preventing deterioration.
- In the examples of the present invention, the kidney injury-related disease is renal fibrosis, renal inflammation, a chronic kidney disease, an acute kidney disease, a renal tubular injury, renal failure, a prerenal injury, a renal induced injury, a postrenal injury, glomerulitis, pyelonephritis, nephrotic syndrome, uremia, or the like.
- In an example of the present invention, the kidney injury-related disease has a mitochondrial injury and at least one of the following symptoms: Proteinuria, edema, oliguria, high urea nitrogen, high creatinine, abnormal uric acid, kidney stone, and an abnormal glomerular filtration rate,
- In another example of the present invention, the mitochondria are separated out from stem cells, such as adipose-derived stem cells, CD34+ hematopoietic stem cells, mesenchymal stem cells, bone stem cells, umbilical stem cells, amniotic stem cells, amniotic fluid stem cells, placental stem cells, iPS, or neural stem cells.
- In the examples of the present invention, the dose of the mitochondria in the composition ranges from 5 μg to 80 μg, and is preferably 40 μg or more.
- The beneficial effects of the present invention are:
- When the mitochondrial damage occurs in kidney cells due to fibrosis, oxidative stress or inflammatory environment, administration of the mitochondrial extract or the composition containing the mitochondrial extract provided by the present invention can effectively improve the mitochondrial damage of kidney cells, therefore it can improve or treat renal cell damage or related diseases.
-
FIG. 1A shows a statistical analysis result of a survival rate of renal epithelial cells subjected to treatment with different concentrations of hydrogen peroxide for 24 hours; -
FIG. 1B shows a statistical analysis result of a survival rate of renal epithelial cells subjected to treatment with different concentrations of hydrogen peroxide and then administered with different doses of mitochondrial precipitates; -
FIG. 2A shows a detection and analysis result of a collagen secretion amount from the renal epithelial cells after the cells are subjected to treatment with different concentrations of Advanced glycation end-products (AGEs-B SA) for different lengths of time; -
FIG. 2B shows a detection and analysis result of a collagen secretion amount from the renal epithelial cells after the cells are subjected to treatment with different concentrations of AGES-BSA and then administered with different doses of mitochondrial precipitates; -
FIG. 2C shows a detection and analysis result of a collagen secretion amount from the renal epithelial cells after the cells are subjected to treatment with different concentrations of hydrogen peroxide and then administered with different doses of mitochondrial precipitates; and -
FIG. 3 shows a detection and analysis result of a mitochondrial injury in the renal epithelial cells after the cells are subjected to treatment with hydrogen peroxide or AGEs-BSA and then administered with different doses of mitochondrial precipitates. - The present invention provides a second use of a mitochondrial extract, which can effectively alleviate a kidney injury-related disease and prevent the progression of the disease by administering a certain amount of mitochondrial extracts or a composition containing the mitochondrial extracts to a patient having the kidney injury-related disease.
- Generally speaking, the patient administration dose of the mitochondria disclosed in the present invention ranges from 5 μg to 80 μg, such as 5 μg, 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 40 μg, 50 μg, 60 μg, 65 μg, 70 μg, or 80 μg, and preferably ranges from 15 μg to 40 μg. Moreover, in order to better treat or alleviate the kidney disease, the mitochondria disclosed in the present invention can be mixed with another component to prepare a composition, where the used component is preferably a material having growth factors, such as a blood product containing growth factors, platelet-rich plasma (PRP), plasma, serum, platelet-rich fibrin (PRF), or the like.
- The “mitochondrial extract” mentioned in the present invention refers to mitochondria separated out from cells, and the used separation technique or method should be able to maintain the structural and functional integrity of the mitochondria. For those of ordinary skill in the art to which the present invention pertains, the separation technique or method may be physical or chemical.
- The “cells” mentioned in the present invention refer to those having mitochondria, such as adipose-derived stem cells, mesenchymal stem cells, skeletal muscle cells, liver cells, kidney cells, fibroblasts, nerve cells, skin cells, blood cells, and the like.
- The “composition” mentioned in the present invention refers to a medical compound, food, functional food, nutritional supplement, etc., and is formed by mixing different components according to different types, to obtain different dosage forms and different administration methods.
- The “kidney injury-related disease” mentioned in the present invention refers to a disease caused by damage to kidney cells and has symptoms of a mitochondrial injury, such as renal fibrosis, renal inflammation, a renal disease, an acute kidney disease, a renal tubular injury, renal failure, a prerenal injury, a renal induced injury, a postrenal injury, glomerulitis, pyelonephritis, nephrotic syndrome, uremia, or the like.
- In order to prove the efficacy of the mitochondrial extract disclosed in the present invention, detailed description is given below by using several examples with reference to the accompanying drawings.
- The mitochondria used in the following examples are taken from human adipose-derived stem cells, but the mitochondria of the present invention are not limited to only coming from the human adipose-derived stem cells. That is, the mitochondria of the present invention can be taken from any human cell.
- The doses of the mitochondria used in the following examples are merely exemplary, where the dose of 15 μg of the mitochondria is used as a low-dose representative and the dose of 40 μg is used as a high-dose representative; and the doses are not intended to limit the technical features of the present invention. That is, the doses of 5 μg to 80 μg of the mitochondria disclosed in the present invention can all achieve the effects to be achieved by the present invention.
- The culture of renal epithelial cell strains was performed in a cell culture medium that contains MEM-α Earl's salt and 5% fetal calf serum in a 37° C. environment (containing 5% carbon dioxide). When the cells were cultured to reach the completeness of 80%, the cell culture medium was removed and the phosphate buffer solution was used for rinsing the cells. Afterwards, the phosphate buffer solution was removed and 0.25% trypsin or 2.21 mM EDTA was added in to react for 20 min, then MEM-α containing 5% fetal calf serum was added in to neutralize the trypsin, and cells in suspension were collected and centrifuged. Then, the cells were counted, and diluted by using MEM-α containing 5% fetal calf serum to a final concentration of 5×104 cells per ml, for use in the subsequent subculture or analysis.
- The human adipose-derived stem cells were cultured to obtain 1.5×108 cells, and the Duchenne phosphate buffer solution (DPBS) was used to flush the cells and then was removed. Trypsin was added in to react for 3 min, and then a stem cell culture liquid (Keratinocyte SFM (1X) liquid, bovine pituitary extract, or 10 wt % fetal calf serum) was added in to terminate the reaction. Afterwards, the cells were collected and centrifuged (600 g for 10 min), and the supernatant was removed. Then, 80 ml IBC-1 buffer solution (the buffer solution is compounded of 225 mM mannitol, 75 mM sucrose, 0.1 mM EDTA, and 30 mM Tris-HCl with pH of 7.4) was added to the cells, and centrifugation was conducted after homogenization, to obtain a precipitate which was the mitochondria (referred to as a mitochondrial precipitate in the following description). 1.5 ml IBC-1 buffer solution and a proteolytic enzyme inhibitor were added to the mitochondrial precipitate, and then the mitochondrial precipitate was placed aside in a 4° C. environment, for use in the following examples.
- The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate, where the concentration per well was 5×104 cells/200 μL. After 8-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing. Afterwards, 2004, cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 8 hours, and after culturing, different concentrations of hydrogen peroxide (0.3 mM, 0.5 mM, 1 mM, 3 mM, 5 mM, and 10 mM) were separately added for treatment. After 24-hour culturing with the different concentrations of hydrogen peroxide, the supernatant was removed from each well and a cell culture liquid (100 μL/well) containing 10% alamar blue was added. After culturing for 3 to 4 hours, fluorescent signal measurement (Excitation/Emission: 560/590 nm) was performed, to obtain a result shown in
FIG. 1A . - It can be known from the result of
FIG. 1A that, after the renal epithelial cells are subjected to treatment with different concentrations of hydrogen peroxide for 24 hours, these cells are likely to get injured, where when the concentration of the hydrogen peroxide is 1 mM or more, there is a significant increase in death of the renal epithelial cells due to the injury. Specifically, after the renal epithelial cells are treated for 24 hours by using hydrogen peroxide with a concentration of 1 mM, the survival rate of the renal epithelial cells is 81.4%; after the renal epithelial cells are treated for 24 hours by using hydrogen peroxide with a concentration of 5 mM, the survival rate of the renal epithelial cells is 31.3%; and after the renal epithelial cells are treated for 24 hours by using hydrogen peroxide with a concentration of 10 mM, the survival rate of the renal epithelial cells is 24.2%. Such a result shows that treating the renal epithelial cells with the hydrogen peroxide can indeed construct an injury and death pattern of the renal epithelial cells; and moreover, as the concentration of the added hydrogen peroxide increases, the injury in the renal epithelial cells worsens and the number of dying renal epithelial cells also rises. - The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate, where the concentration per well was 1×104 cells/200 μL. After 8-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing. Afterwards, 2000 μL cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 8 hours. After culturing, hydrogen peroxide with the concentrations of 1 mM and 3 mM was separately added in for treatment for 4 hours, and then different doses (15 μg and 40 μg) of mitochondrial precipitates (prepared in Example 2) were administered to the cells treated with the different concentrations of hydrogen peroxide, to perform culturing for 24 hours. After culturing completion, the supernatant was removed and a cell culture liquid (100 μL/well) containing 10% alamar blue was added. After culturing for 3 to 4 hours in a 37° C. environment, fluorescent signal measurement (Excitation/Emission: 560/590 nm) was performed after culturing completion, to obtain a result shown in
FIG. 1B . - It can be known from the result of
FIG. 1B that, the survival rate of the renal epithelial cells decreases because the cells are injured after treatment with the hydrogen peroxide. When the renal epithelial cells are injured due to induction by the hydrogen peroxide and then a certain amount of mitochondrial precipitates are added, the survival rate of the renal epithelial cells can be significantly improved. Moreover, as the administration dose increases, the survival rate of the renal epithelial cells also rises. - It can be known from the result that, the mitochondrial extract disclosed in the present invention can indeed protect the renal epithelial cells against injuries caused by oxidation or inflammation, and can repair the injured renal epithelial cells, thus efficiently avoiding the renal epithelial cells from death. In other words, the mitochondrial extract disclosed in the present invention or a composition containing the mitochondrial extract can indeed alleviate and/or prevent a kidney injury or kidney disease due to oxidative stress.
- The renal epithelial cells cultured in Example 1 were cultured in a 6-well plate by using a culture liquid containing 5% fetal calf serum, where the concentration per well was 1×105 cells/2 ml. After 24-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing. Afterwards, 1 ml cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 8 hours. Then, different concentrations (100 μg/ml and 400 μg/ml) of Advanced Glycation End product-BSA (AGES-BSA) were administered to perform culturing for 4 hours. After culturing completion, the cell culture medium containing AGEs-B SA was removed and the phosphate buffer solution was used for rinsing. Then, 1 ml cell culture liquid not containing 5% fetal calf serum was added to each well for culturing for 24 and 48 hours separately, and the supernatant was separately collected after culturing completion. A collagen secretion assay was performed by using the Sircol™ Soluble Collagen Assay Kit, to obtain a result shown in
FIG. 2A . - It can be known from the result of
FIG. 2A that, whether the renal epithelial cells are treated with a high (400 μg/ml) or low (100 μg/ml) concentration of AGEs-B SA, the secretory expression amount of collagen from the renal epithelial cells can be improved, and rises as the treatment time increases. It indicates that AGEs-BSA can indeed induce lesions to the renal epithelial cells and cause fibrosis, which is the early stage of the chronic kidney disease. Moreover, if the secretory expression amount of collagen continuously increases, the chronic kidney disease is caused. - The process of this example was substantially identical with that in Example 5, but had the following differences. In this example, after the cell culture medium containing AGEs-B SA was removed, a cell culture liquid not containing 5% fetal calf serum and different doses (15 μg and 40 μg) of mitochondrial precipitates (prepared in Example 2) were added to each well for separately culturing for 24 hours. After culturing completion, the supernatant was separately collected and a collagen secretion assay was performed by using the soluble collagen assay kit, to obtain a result shown in
FIG. 2B . - It can be known from the result of
FIG. 2B that, the administration of the mitochondrial precipitates can reduce the amount of collagen secretion induced by AGEs-BSA in the renal epithelial cells, which indicates that the mitochondria or a composition containing the mitochondria disclosed in the present invention can efficiently alleviate and/or prevent kidney fibrosis or the related kidney diseases. - The process of this example was substantially identical with that in Example 6, but had the following difference. The stimulant that induces fibrosis in the renal epithelial cells was changed from AGEs-BSA to hydrogen peroxide, to obtain a result shown in
FIG. 2C . - It can be known from the result of
FIG. 2C that, the treatment of the renal epithelial cells with the hydrogen peroxide can induce an increase in the collagen secretion amount, that is, the treatment of the renal epithelial cells with the hydrogen peroxide can indeed construct a pattern of renal cell fibrosis. After mitochondrial precipitates are administered to the renal epithelial cells subjected to treatment with the hydrogen peroxide, the collagen secretion amount in the renal epithelial cells can be obviously reduced, which indicates that the mitochondria or a composition containing the mitochondria disclosed in the present invention can efficiently alleviate and/or prevent kidney fibrosis or the related kidney diseases. - The renal epithelial cells cultured in Example 1 were subcultured in a 96-well plate by using a cell culture liquid containing 5% fetal calf serum, where the concentration per well was 5×104 cells/200 μL. After 24-hour culturing, the supernatant was removed and the phosphate buffer solution was used for rinsing; and then 1 ml cell culture liquid not containing 5% fetal calf serum was added to each well to perform culturing for 8 hours. After culturing, 3 mM hydrogen peroxide and 100 μg/ml AGEs-BSA were separately administered to perform culturing for 4 hours; and then the cell culture liquid containing hydrogen peroxide or AGEs-BSA was removed, and the phosphate buffer solution was used for rinsing. Afterwards, 1 ml cell culture liquid not containing 5% fetal calf serum and different doses (15 μg and 40 μg) of mitochondrial precipitates (prepared in Example 2) were added to each well, to perform culturing for 24 hours separately. After culturing completion, the phosphate buffer solution was used for rinsing, and a buffer solution containing 10 μM JC-1 staining reagent was then added in to react for 10 min at 37° C. After rinsing, fluorescent signal measurement (Excitation/Emission: 488/530 nm) was performed, to obtain a result shown in
FIG. 3 . - It can be known from the result of
FIG. 3 that the expression level of the JC-1 monomer in the renal epithelial cells subjected to treatment with only the hydrogen peroxide or AGEs-BSA increases, which indicates that mitochondria in the renal epithelial cells are injured due to an inflammatory environment caused by the hydrogen peroxide or AGEs-BSA. When the renal epithelial cells are treated first by using the hydrogen peroxide or AGEs-BSA and then by using different doses of mitochondrial precipitates, the expression level of the JC-1 monomer therein obviously decreases. Moreover, as the dose of the mitochondrial precipitates increases, the expression level of the JC-1 monomer in the renal epithelial cells decreases. - 10-week-old C57BL/6 mice were used and raised at constant temperature and humidity, with a 12-hour light/dark cycle. An ischemia-reperfusion (referred to as an “I/R kidney injury pattern” in the following description) pattern was used as the kidney injury pattern of the mice, and the steps were as follows: First, intraperitoneal injection was conducted and 150 mg/Kg phenobarbital was injected into the abdomen of each mouse. When the mouse was unconscious, surgery was performed on the left kidney of the mouse. The left kidney was moved to the outside from the incision, and then the blood vessel for the renal artery to flow into the kidney was blocked with a vascular clamp. After blocking for 30 min, the vascular clamp was removed to allow the blood flow to pass, thus completing the I/R kidney injury pattern.
- For the mice subjected to treatment of the UR kidney injury pattern, different doses (15 μg and 40 μg) of mitochondria were delivered to the kidney by means of injection through the renal artery vessel, to form a high mitochondrial dose group and a low mitochondrial dose group. For the control group (I/R group), the phosphate buffer solution was injected. After completion of treatment for the mice in each group, the kidneys were separately moved back into the bodies and the wounds were sutured; and on the first day (D1) and the second day (D2) after surgery for each group of mice, the blood samples were collected, and the serum creatinine (Cr) and the blood urea nitrogen (BUN) were measured. Afterwards, the drawn blood was centrifuged and the serum was collected after separation, to analyze the contents of urea nitrogen and creatinine in the serum, where the detection of serum creatinine was made by using a mouse creatinine analysis kit (Brand: Crystal Chem; Model: 80350) and the detection of urea nitrogen was made by using a urea analysis kit (Brand: abcam; Model: ab83362). When the mice in each group were sacrificed on the 7th day (D7) after transplantation, the left kidney of each mouse was perfused and fixed with formalin, then was paraffin-embedded and histologically sectioned, and finally was subjected to H&E staining. According to morphological changes caused by an ischemic injury based on histological studies for the staining result, the degree of kidney injuries was scored as follows by using the Jablonski's semi-quantitative criteria: 0 for normal tissue; 1 for the renal tubular injury area of less than 5%; 2 for the renal tubular injury area of more than 5% to less than 25%; 3 for the renal tubular injury area of greater than 25% to less than 75%; and 4 for the renal tubular injury area of greater than 75%.
- The foregoing results are shown in the following table 1. It can be known from the results of table 1 that, compared to the control group, the expression amounts of the urea nitrogen and the creatinine in the serum of the FR group obviously increase, which indicates that the FR kidney injury pattern can indeed cause a kidney injury. Moreover, it can be known from the scoring result of the kidney injury that, the score of the FR group is 3-4, indicating a severe renal tubular injury. However, compared to the FR group, the contents of urea nitrogen and creatinine in the serum of the mice in the group administered with the mitochondria obviously decrease, which indicate that the administration of the mitochondria can effectively alleviate the kidney injury. It can be further known from the scoring result of the kidney injury that, the administration of the mitochondria can recover the injured kidney cells and alleviate the renal tubular injury; and as the administration dose of the mitochondria increases, a better effect of alleviating the kidney injury can be achieved.
-
TABLE 1 Analysis results of serum and kidney tissue sections after different treatment for the mice in each group Low High mitochondrial mitochondrial dose group dose group Control group I/R group (15 μg) (40 μg) D1: Urea 19 ± 1.8 61 ± 2.6 25 ± 2.3 24 ± 2.4 nitrogen in the serum (mg/dL) D2: Urea 21 ± 1.6 119 ± 2.2 63 ± 1.9 41 ± 2.1 nitrogen in the serum (mg/dL) D1: Creatinine 0.23 ± 0.024 0.41 ± 0.021 0.31 ± 0.023 0.29 ± 0.025 in the serum (mg/dL) D2: Creatinine 0.22 ± 0.03 0.59 ± 0.022 0.42 ± 0.026 0.34 ± 0.031 in the serum (mg/dL) D7: Scores of 0 3.7 ± 0.32 2.9 ± 0.29 1.8 ± 0.35 kidney injury - The foregoing results show that, when the mitochondria in the kidney cells are injured due to fibrosis, oxidative stress or inflammation, the administration of the mitochondrial extract disclosed in the present invention or a composition containing the mitochondrial extract can effectively alleviate the mitochondrial injury in the kidney cells, thus alleviating or treating the kidney cell injury or its related diseases.
Claims (9)
1. A use of mitochondria to prepare a composition for preventing and/or treating a kidney injury-related disease.
2. The use of claim 1 , wherein the kidney injury-related disease is kidney fibrosis.
3. The use of claim 1 , wherein the kidney injury-related disease is kidney inflammation.
4. The use of claim 1 , wherein the kidney injury-related disease has a symptom of a mitochondrial injury.
5. The use of claim 1 , wherein the kidney injury-related disease is a chronic kidney disease.
6. The use of claim 1 , wherein the kidney injury-related disease is a renal tubular injury.
7. The use of claim 6 , wherein the symptom of the renal tubular injury is that the injury area is greater than 25%.
8. The use of claim 1 , wherein the dose of the mitochondria in the composition is 5 μg or more.
9. The use of claim 1 , wherein the dose of the mitochondria in the composition is 40 μg or more.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/912,394 US20230137870A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondrial extract to treat and/or prevent kidney injury-related disease |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062992546P | 2020-03-20 | 2020-03-20 | |
US17/912,394 US20230137870A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondrial extract to treat and/or prevent kidney injury-related disease |
PCT/CN2021/081686 WO2021185341A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondrial extract for treatment or/and prevention of kidney injury-related diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230137870A1 true US20230137870A1 (en) | 2023-05-04 |
Family
ID=77768010
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/912,394 Pending US20230137870A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondrial extract to treat and/or prevent kidney injury-related disease |
US17/912,336 Pending US20230042445A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondria to promote wound repair and/or wound healing |
US17/912,458 Pending US20230165899A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondria to treat and/or prevent tendon injury or its related disease |
US17/948,007 Pending US20230023438A1 (en) | 2020-03-20 | 2022-09-19 | Composition comprising mitochondria and use thereof for repairing cartilage damage or improving osteoarthritis |
US17/947,994 Pending US20230023218A1 (en) | 2020-03-20 | 2022-09-19 | Use of a cell culture composition for promoting cell growth |
US17/948,764 Pending US20230016499A1 (en) | 2020-03-20 | 2022-09-20 | Method for manufacturing mitochondria-rich plasma |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/912,336 Pending US20230042445A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondria to promote wound repair and/or wound healing |
US17/912,458 Pending US20230165899A1 (en) | 2020-03-20 | 2021-03-19 | Use of mitochondria to treat and/or prevent tendon injury or its related disease |
US17/948,007 Pending US20230023438A1 (en) | 2020-03-20 | 2022-09-19 | Composition comprising mitochondria and use thereof for repairing cartilage damage or improving osteoarthritis |
US17/947,994 Pending US20230023218A1 (en) | 2020-03-20 | 2022-09-19 | Use of a cell culture composition for promoting cell growth |
US17/948,764 Pending US20230016499A1 (en) | 2020-03-20 | 2022-09-20 | Method for manufacturing mitochondria-rich plasma |
Country Status (6)
Country | Link |
---|---|
US (6) | US20230137870A1 (en) |
EP (2) | EP4122474A4 (en) |
JP (1) | JP2023518083A (en) |
CN (12) | CN118319951A (en) |
TW (8) | TW202404618A (en) |
WO (6) | WO2021185341A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116478920A (en) * | 2023-05-05 | 2023-07-25 | 重庆理工大学 | In vitro storage method of isolated mitochondria |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7005274B1 (en) * | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
BRPI0507349A (en) * | 2004-02-02 | 2007-04-17 | Nestec Sa | genes associated with canine osteoarthritis and related processes and compositions |
WO2009002811A2 (en) * | 2007-06-22 | 2008-12-31 | Children's Medical Center Corporation | Therapeutic platelet compositions and methods |
US8734854B2 (en) * | 2009-07-09 | 2014-05-27 | Orogen Biosciences Inc. | Process for removing growth factors from platelets |
US20130022666A1 (en) * | 2011-07-20 | 2013-01-24 | Anna Brzezinska | Methods and compositions for transfer of mitochondria into mammalian cells |
WO2013035101A1 (en) * | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
EP2591812A1 (en) * | 2011-11-14 | 2013-05-15 | University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) | A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair |
US20140024677A1 (en) * | 2012-04-09 | 2014-01-23 | Musc Foundation For Research Development | Methods for inducing mitochondrial biogenesis |
US10702556B2 (en) * | 2012-05-16 | 2020-07-07 | Minovia Therpautices Ltd. | Compositions and methods for inducing angiogenesis |
WO2014121481A1 (en) * | 2013-02-07 | 2014-08-14 | 李震义 | Use of long-acting human recombinant soluble tumour necrosis factor α receptor in the preparation of drugs for preventing and treating chronic liver diseases and severe liver damage |
US20150064715A1 (en) * | 2013-08-28 | 2015-03-05 | Musc Foundation For Research Development | Urinary biomarkers of renal and mitochondrial dysfunction |
TW201509425A (en) * | 2013-09-13 | 2015-03-16 | Taichung Hospital Ministry Of Health And Welfare | Method of using blood to prepare pharmaceutical composition for repairing wound |
TWI672147B (en) * | 2014-09-10 | 2019-09-21 | 台灣粒線體應用技術股份有限公司 | Exogenous mitochondria as a composition of active ingredients, use thereof and method of repairing cells |
CN105520891B (en) * | 2014-09-30 | 2019-05-21 | 台湾粒线体应用技术股份有限公司 | Using exogenous mitochondria as the method for the composition of effective ingredient, its purposes and repair cell |
WO2016106660A1 (en) * | 2014-12-31 | 2016-07-07 | 国立中兴大学 | Novel pharmaceutical composition and use thereof for treating lung injury |
BR112017015004A2 (en) * | 2015-01-15 | 2018-01-23 | K Boss William Jr | tissue repair and rejuvenation using platelet-rich plasma. |
CN104546915B (en) * | 2015-02-16 | 2018-12-11 | 天晴干细胞股份有限公司 | A kind of preparation method of composition that treating Osteoarthritis |
JP7015169B2 (en) * | 2015-02-26 | 2022-02-02 | ミノヴィア セラピューティクス リミテッド | Mammalian cells enriched with functional mitochondria |
CN105030647B (en) * | 2015-09-14 | 2018-04-24 | 广州赛莱拉干细胞科技股份有限公司 | A kind of preparation for reducing wrinkle and preparation method thereof |
JP2018535749A (en) * | 2015-11-02 | 2018-12-06 | ベリグラフト アーベー | Compositions and methods for healing wounds |
CN105477018A (en) * | 2015-12-07 | 2016-04-13 | 深圳爱生再生医学科技有限公司 | Stem cell-based medicinal product for repairing skin ulcer and preparation method of stem cell-based medicinal product for repairing skin ulcer |
CN109152795A (en) * | 2016-01-15 | 2019-01-04 | 儿童医学中心公司 | The therapeutical uses of mitochondria and combined mitochondria reagent |
US20170224764A1 (en) * | 2016-02-10 | 2017-08-10 | Cornell University | Therapeutic targeting of mitochondria to prevent osteoarthritis |
TWI637748B (en) * | 2016-07-12 | 2018-10-11 | 中山醫學大學 | Use of lotus root extract for treating and / or preventing kidney disease |
CN106190963A (en) * | 2016-07-13 | 2016-12-07 | 浙江大学 | A kind of method using mitochondrial transplantation to promote injured neuron survival |
JP2020502078A (en) * | 2016-11-30 | 2020-01-23 | パイアン・バイオテクノロジー・インコーポレイテッドPaean Biotechnology Inc. | Pharmaceutical composition containing mitochondria |
CN106822183B (en) * | 2016-12-26 | 2020-04-14 | 中山光禾医疗科技有限公司 | Photosensitive platelet-rich plasma gel and preparation method and application thereof |
WO2018178970A1 (en) * | 2017-03-26 | 2018-10-04 | Minovia Therapeutics Ltd. | Mitochondrial compositions and methods for treatment of skin and hair |
EP3624830A4 (en) * | 2017-05-15 | 2020-12-30 | Miron, Richard J. | Liquid platelet-rich fibrin as a carrier system for biomaterials and biomolecules |
US10940241B2 (en) * | 2017-06-01 | 2021-03-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formation of stable cartilage |
US20190008896A1 (en) * | 2017-07-07 | 2019-01-10 | Richard Postrel | Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions |
CN107625969A (en) * | 2017-10-18 | 2018-01-26 | 南京市儿童医院 | The antagonists of MiR 214 are preparing the purposes in being used to mitigate the medicine of renal damage associated conditions caused by albuminuria |
WO2019083201A2 (en) * | 2017-10-24 | 2019-05-02 | 주식회사 엑소코바이오 | Use of composition comprising adipose stem cell-derived exosome as effective ingredient in improving renal function |
KR20190052266A (en) * | 2017-11-08 | 2019-05-16 | 원광대학교산학협력단 | Composition of the improvement or treatment of kidney function comprising ursolic acid as active ingredient |
EP3747449A4 (en) * | 2018-02-02 | 2021-10-20 | Paean Biotechnology Inc. | Pharmaceutical composition comprising isolated mitochondria for prevention or treatment of rheumatoid arthritis |
CA3093823A1 (en) * | 2018-03-13 | 2019-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Transient cellular reprogramming for reversal of cell aging |
WO2019183042A1 (en) * | 2018-03-20 | 2019-09-26 | Unity Biotechnology, Inc. | Autologous mitochondrial extraction and expansion |
US20210275587A1 (en) * | 2018-07-22 | 2021-09-09 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
AU2019311862A1 (en) * | 2018-07-22 | 2021-02-04 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria |
WO2020054829A1 (en) * | 2018-09-14 | 2020-03-19 | ルカ・サイエンス株式会社 | Transplantation of mitochondria into lymphoid organ and composition therefor |
WO2020091463A1 (en) * | 2018-10-31 | 2020-05-07 | 차의과학대학교 산학협력단 | Pharmaceutical composition comprising isolated mitochondria for preventing or treating tendinopathy |
CN110055216A (en) * | 2019-05-09 | 2019-07-26 | 张秀明 | A method of improving interstital stem cell biological function |
CN110638833A (en) * | 2019-11-15 | 2020-01-03 | 西安圣德生物科技有限公司 | Composition for promoting hair growth and method of use thereof |
CN110812480B (en) * | 2019-11-28 | 2021-04-02 | 中国科学院昆明动物研究所 | Antibacterial peptide and mitochondrial DNA compound, polyclonal antibody and application thereof |
-
2021
- 2021-03-18 TW TW112139490A patent/TW202404618A/en unknown
- 2021-03-18 TW TW111140519A patent/TWI827321B/en active
- 2021-03-18 TW TW110109766A patent/TWI789723B/en active
- 2021-03-18 TW TW110109767A patent/TWI789724B/en active
- 2021-03-18 TW TW110109765A patent/TWI787761B/en active
- 2021-03-19 CN CN202410329264.5A patent/CN118319951A/en active Pending
- 2021-03-19 EP EP21770630.8A patent/EP4122474A4/en active Pending
- 2021-03-19 JP JP2022556517A patent/JP2023518083A/en active Pending
- 2021-03-19 CN CN202311570784.7A patent/CN117357559A/en active Pending
- 2021-03-19 WO PCT/CN2021/081686 patent/WO2021185341A1/en active Application Filing
- 2021-03-19 US US17/912,394 patent/US20230137870A1/en active Pending
- 2021-03-19 WO PCT/CN2021/081854 patent/WO2021185364A1/en active Application Filing
- 2021-03-19 CN CN202410329249.0A patent/CN118319950A/en active Pending
- 2021-03-19 TW TW110109874A patent/TWI796653B/en active
- 2021-03-19 CN CN202180022924.XA patent/CN115335065A/en active Pending
- 2021-03-19 CN CN202180014788.XA patent/CN115315265B/en active Active
- 2021-03-19 WO PCT/CN2021/081685 patent/WO2021185340A1/en active Application Filing
- 2021-03-19 TW TW111141019A patent/TW202308668A/en unknown
- 2021-03-19 CN CN202180014777.1A patent/CN115103683B/en active Active
- 2021-03-19 WO PCT/CN2021/081687 patent/WO2021185342A1/en active Application Filing
- 2021-03-19 US US17/912,336 patent/US20230042445A1/en active Pending
- 2021-03-19 US US17/912,458 patent/US20230165899A1/en active Pending
- 2021-03-19 CN CN202180014670.7A patent/CN115135328B/en active Active
- 2021-03-19 TW TW110109873A patent/TWI787763B/en active
- 2021-03-19 CN CN202311621466.9A patent/CN117379458A/en active Pending
- 2021-03-22 EP EP21770632.4A patent/EP4122444A4/en active Pending
- 2021-03-22 CN CN202180022422.7A patent/CN115297872B/en active Active
- 2021-03-22 CN CN202410414731.4A patent/CN118252850A/en active Pending
- 2021-03-22 CN CN202180022370.3A patent/CN115315248A/en active Pending
- 2021-03-22 WO PCT/CN2021/082094 patent/WO2021185376A1/en active Application Filing
- 2021-03-22 CN CN202410414725.9A patent/CN118236473A/en active Pending
- 2021-03-22 WO PCT/CN2021/082117 patent/WO2021185377A1/en active Application Filing
-
2022
- 2022-09-19 US US17/948,007 patent/US20230023438A1/en active Pending
- 2022-09-19 US US17/947,994 patent/US20230023218A1/en active Pending
- 2022-09-20 US US17/948,764 patent/US20230016499A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230137870A1 (en) | Use of mitochondrial extract to treat and/or prevent kidney injury-related disease | |
Hassanzadeh et al. | FNDC5 expression in Purkinje neurons of adult male rats with acute spinal cord injury following treatment with methylprednisolone | |
Li et al. | Gomisin N attenuated cerebral ischemia-reperfusion injury through inhibition of autophagy by activating the PI3K/AKT/mTOR pathway | |
Yuvanc et al. | Investigation of the antioxidant effects of pheniramine maleate and nebivolol on testicular damage in rats with experimentally induced testis torsion | |
US20230021803A1 (en) | Placental tissue particulate compositions and methods of use | |
KR102128003B1 (en) | Pharmaceutical composition for preventing or treating tendinopathy comprising isolated mitochondria | |
MARKS et al. | Carcinoma of the lung associated with marked adrenocortical hyperplasia and adrenal hyper-responsiveness to ACTH in the absence of Cushing's syndrome | |
CN111658655A (en) | Application of cucurbitacin B in preparation of iron death inducer and anti-nasopharyngeal carcinoma drug | |
JPH01151514A (en) | Treating and preventive agent for neuropathy | |
US8409632B2 (en) | Product containing extract from Zanthoxylum avicennae (Lam.) DC., and preparation process and use thereof | |
US20220008377A1 (en) | Composition for preventing or treating cellular senescence-related diseases comprising salinomycin as effective component | |
KR20220028557A (en) | Composition of membrane free stem cell for improvng oxidative stress | |
KR20050088950A (en) | A food composition comprising scrophularia buergeriana extract with anti-aging activity | |
Yan et al. | Role of Autophagy in Rat Acute Spinal Cord Injury Induced by Rapamycin | |
CN117942334B (en) | NLRP3 inflammation small body activation inhibitor and preparation method and application thereof | |
US20240115538A1 (en) | Aggrelytes for treating ocular conditions | |
Wang et al. | PEP-1-SOD1 improves the therapeutic potential of transplanted adipose-derived mesenchymal stem cells in spinal cord injury | |
Sutadji et al. | SS-31 protects diabetic nephropathy progression: A systematic review of in vivo and in vitro studies | |
EP4353234A1 (en) | Use of pyrrolopyrimidine compound | |
US20210244773A1 (en) | Dental pulp stem cells and uses thereof | |
Adamczak et al. | Carbohydrate metabolism in chronic renal disease | |
CN114601841A (en) | Application of marsdenia tenacissima glycoside G in preparation of medicine for preventing and/or treating osteoarthritis | |
Denis | The influence of salicylates on the elimination of uric acid and other waste products from the blood | |
CN110934888A (en) | Novel electrolytic glycoside therapeutic pharmaceutical composition | |
CN118320055A (en) | Application of dipeptide Gly-Lys in preparation of medicine for treating acute kidney injury |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD., TAIWAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHENG, HAN-CHUNG;HSU, CHIH-KAI;TSENG, HUI-CHING;SIGNING DATES FROM 20220803 TO 20220805;REEL/FRAME:061523/0266 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |